Our Parliamentary Affairs and Policy and Evidence teams have submitted their calls to the Government as part of the feedback process for the Spending Review.

The Royal Society, as our national science academy, holds a unique and leading position within the UK scientific community, a position that in the Society’s own words “rests upon the reputation of the ...

This collaboration supports the ‘Green Navy’ initiative, aiming for a sustainable and environmentally responsible future ...

No sector is left unchanged by the power of AI and digital modeling, and Biotech is no exception. This is because biology is by far the most “messy” of hard sciences. Chemistry or physics can deal ...

Biotech stocks are companies that use living organisms to make drugs and vaccines. Often, they merge cutting-edge technology with new findings in molecular science and virology to treat life ...

Robson Green may live in a ferryman's cottage in Hexham ... Charles similarly loves meals made with homegrown ingredients. The royal bought Highgrove House in 1980, and he first lived there ...

“hang,” which debuted at the Royal Court Theatre in London in 2015 ... for debbie tucker green’s plays are – to varying degrees and in varying ways – explorations of contemporary ...

The Queen also holds a number of patronages, including the Royal Literary Fund, the Royal Academy of Dance, the Royal Voluntary Service and the Army Benevolent Fund, and undertakes her own public ...

A busy working chapel, the Chapel Royal holds regular services which are open to the general public, as well as hosting some unique Royal services. If you would like to attend a service, click on ...

They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...

Primarily, Ascentage hopes to leverage the IPO proceeds to advance its pipeline. Around $50 million to $60 million, for instance, will help the biotech pursue approval for its BCL-2 blocker ...

The biotech firm's mRNA-1018 candidate posted positive results in a Phase 1/2 study launched in 2023. Moderna plans to move mRNA-1018 to a Phase 3 trial. Shares of Moderna (MRNA) took off Tuesday ...